Sign Up Today and Learn More About Sutro Biopharma Stock
Invest in or calculate the value of your shares in Sutro Biopharma or other pre-IPO companies through EquityZen's platform.
Sutro Biopharma Stock
Develops protein therapeutics by using OCFS protein synthesis technology
About Sutro Biopharma Stock
Founded
2003
Headquarters
South San Francisco, CA, US
Total Funding
202M
Industries
Software, Data and Analytics, Artificial Intelligence
Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease. Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.
Sutro Biopharma Press Mentions
Stay in the know about the latest news on Sutro Biopharma
Sutro Biopharma Strikes $1.6 Billion Drug-Development Deal With Merck
Wall Streets Journal • Jul 24, 2018
Sutro Biopharma Management
Leadership team at Sutro Biopharma
Founder & Director
James R. Swartz
Vice President of Development and Manufacturing
Henry Heinsohn
Join now and verify your accreditation status to gain access to:
- Sutro Biopharma current valuation
- Sutro Biopharma stock price
- Available deals in Sutro Biopharma and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Sutro Biopharma stock?
Accredited investors can buy pre-IPO stock in companies like Sutro Biopharma through EquityZen funds. These investments are made available by existing Sutro Biopharma shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Sutro Biopharma stock?
Shareholders can sell their Sutro Biopharma stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
